IL-17 stimulation is required to produce antibodies against staphylococci 33, which increases the risk of severe staphylococcal infections in patients with anti-IL-17 antibodies, like those with deficits in the STAT3 signaling pathway. Here, IL17A is linked to staphylococcal infection.